Daewoong Pharmaceutical has signed an agreement with Cooper Pharma for the licence and distribution of their potassium-competitive acid blocker (P-CAB) drug, Fexuprazan, for the improvement of digestive health in Morocco.
As per the agreement, Fexuprazan is scheduled to be locally released in the Moroccan market in 2025. The partnership agreement between Daewoong Pharmaceutical and Cooper Pharma is valued at approximately USD 20.32 million (equivalent to KRW 27 billion).
Through this strategic partnership, Daewoong Pharmaceutical aims to expand the presence of Fexuprazan in Africa, capitalising on its unique properties and efficacy in managing GERD. This move represents an important milestone for both the parties, potentially benefiting patients in Morocco and contributing to the advancement of digestive health solutions in the region.
Fexuprazan is known for its rapid and consistent suppression of gastric acid, regardless of food intake. Additionally, it boasts the longest half-life of 9 hours among P-CABs, providing a longer duration of action compared to other drugs used for GERD treatment.
